The developmental origin of brain tumours: a cellular and molecular framework. by Azzarelli, Roberta et al.
REVIEW
The developmental origin of brain tumours: a cellular and
molecular framework
Roberta Azzarelli1,2,4, Benjamin D. Simons2,3,4 and Anna Philpott1,2,*
ABSTRACT
The development of the nervous system relies on the coordinated
regulation of stem cell self-renewal and differentiation. The discovery
that brain tumours contain a subpopulation of cells with stem/
progenitor characteristics that are capable of sustaining tumour
growth has emphasized the importance of understanding the
cellular dynamics and the molecular pathways regulating neural
stem cell behaviour. By focusing on recent work on glioma and
medulloblastoma, we review how lineage tracing contributed to
dissecting the embryonic origin of brain tumours and how lineage-
specific mechanisms that regulate stem cell behaviour in the embryo
may be subverted in cancer to achieve uncontrolled proliferation and
suppression of differentiation.
Introduction
Neurological cancers are among the most feared malignancies. They
include medulloblastoma, the most common malignant brain
tumour in children, and high-grade glioblastoma, one of the most
lethal adult cancers (Table 1) (Louis et al., 2016). Treatment for
medulloblastoma requires high dose multi-modal chemotherapy
and radiotherapy that come with significant and long-term adverse
consequences, even when a cure is obtained, whereas glioblastoma
is almost invariably fatal even after treatment. Hence, there is a
pressing need to understand more about the biology of these
diseases, so that therapy can be effectively targeted to the malignant
cells and not to the surrounding tissue.
For many years, research has focussed on what different types of
neurological tumours have in common with other malignancies and
with each other, e.g. the disruption of classic oncogenic and tumour
suppressor pathways, but this approach has had little effect on
improving survival rates. More promising perhaps is the emerging
consensus that brain tumours are maintained by a specific neural or
glial cancer ‘stem cell-like’ population that self-renews and gives
rise to differentiated progeny (Galli et al., 2004; Singh et al., 2003,
2004; Vescovi et al., 2006). Whether tumours initiate in stem cell-
like populations or arise from progenitors that, through mutation,
acquire stem cell-like potential remains unknown. Moreover, cancer
stem cells and their progeny can demonstrate considerable plasticity
(Batlle and Clevers, 2017), and brain tumours that arise from them
often harbour mixed cell populations that are very reminiscent of
normal developing brain tissue (Lan et al., 2017; Pollen et al., 2015;
Tirosh et al., 2016).
The possibility that neurological cancers are ‘locked in’ to a
developmental programme and may retain many of the controls that
impinge on these cell populations during development opens up
new and exciting opportunities for understanding and targeting
these cancers. Some of these opportunities are already being
exploited in the treatment of paediatric neurological malignancies,
where the relationship of cancer cells to spatially and temporally
distinct embryonic precursors is better understood (Cavalli et al.,
2017; Phoenix et al., 2012; Ramaswamy et al., 2016). For example,
medulloblastoma can be classified into distinct subgroups depending
on histological features and genetic profiling, and it has become
clear over the years that differences in these subgroups may relate to
their origin within different regions of the cerebellum (Fig. 1)
(Bihannic and Ayrault, 2016; Cavalli et al., 2017; Gibson et al.,
2010; Li et al., 2013; Phoenix et al., 2012). This classification has the
potential to profoundly influence future research and treatment. In
particular, it identifies subgroups of patients with different prognoses
and sensitivity to drugs, which has already influenced therapeutic
intervention strategies in some children (Ramaswamy et al., 2016).
In this Review, we will consider both paediatric and adult central
nervous system tumours through the lens of the developmental
biology paradigms that they exploit to maintain a stem/progenitor
identity, while at the same time producing both proliferating and
differentiating progeny. We will also discuss the extent to which
viewing these cancers as diseases of development might reveal new
therapeutic approaches, exploiting tissue-specific oncogenes and
the aberrant developmental phenotype while sparing normal tissue.
The search for brain tumour stem cells
The stem cell hypothesis of tumour maintenance has become
increasingly prominent in recent years (Batlle and Clevers, 2017). In
this paradigm, bulk tumours are fed by a subpopulation of slow-
cycling stem cell-like cells that harbour tumour-initiating potential.
Cancer stem cells are generally thought to be resistant to treatment,
yet retain the ability to reconstitute the varied cell types within the
heterogeneous tumour mass once treatment ceases. Brain tumours
were among the first cancers in which stem cell-like cells were
identified and isolated in vitro, although how this behaviour relates
to their in vivo role remains somewhat unclear (Galli et al., 2004;
Singh et al., 2003, 2004). A subpopulation of CD133+ cells was
isolated from paediatric human brain tumours that exhibited stem
cell-like properties in vitro and that, when injected in vivo,
recapitulated features of the original tumour, including its
heterogeneous cell composition (Singh et al., 2004). Similarly,
cells with stem-like properties have been isolated from a wide range
of paediatric tumours, such as glioma, medulloblastoma, primitive
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neuroectodermal tumours and ependymoma (Galli et al., 2004;
Hemmati et al., 2003). In common with non-malignant neural
precursor cells, these tumour cells can be grown in vitro, allowing a
direct comparison between normal and tumour stem cells, and
facilitating the identification of drugs that may selectively act on
cancer cells and not their normal counterparts (Bressan et al., 2017;
Pollard et al., 2009).
Tumour cell of origin: stem, progenitor or differentiated cell types?
Brain tumours can arise from stem, progenitor and/or more mature
cells, and one might expect their cell of origin to significantly
influence subsequent cell behaviour. Understanding the cell of
origin of each tumour type may also expose lineage-specific
therapeutic vulnerabilities and/or opportunities to identify early
malignant or even pre-malignant abnormal cell states. Some cells
may certainly be more vulnerable to oncogenic assault than others.
Although functional studies provide strong evidence for stem cell-
like behaviour in certain subpopulations of brain tumours, the
identification of definitive cell surface markers of these cells has
been challenging. For example, while CD133-positive cells have
been shown to harbour tumour-initiating potential, so too have
CD133-negative cells (Beier et al., 2007; Ogden et al., 2008; Read
et al., 2009). The cell surface marker CD15 (also known as stage-
specific embryonic antigen, SSEA1) has been proposed as a general
marker for brain tumour stem cells in both gliomas and
medulloblastomas (Son et al., 2009; Ward et al., 2009). However,
the studies that implicate CD15 have indicated that the ability to
maintain tumours may not reside solely in stem-like cells, but may
extend to cells with a more restricted progenitor-like identity. For
example, a rare population of CD15-positive cells identified in
human medulloblastomas (Read et al., 2009) and from a Ptch1+/−
medulloblastoma mouse model (Read et al., 2009; Ward et al.,
2009) also express ATOH1 (also known as MATH1), and so
resemble granule neuron precursors rather than stem cells. Thus,
although stem cells are thought to reside at the apex of a hierarchy
that maintains tumour growth, several lines of evidence indicate that
actively cycling fate-restricted progenitors might also contribute to
the formation and progression of tumour masses (Vanner et al.,
2014). Indeed, lineage-tracing studies have demonstrated that type I
SHH-driven medullobastomas can be initiated from Atoh1-positive
granule neuron precursors (Schüller et al., 2008; Yang et al., 2008),
whereas oligodendrogliomas, which represent 5-20% of all gliomas,
mainly originate fromNG2-positive oligodendrocyte precursor cells
(Liu et al., 2011; Persson et al., 2010). Intriguingly, in different
mouse models of gliomagenesis, tumour growth potential has been
shown not to correlate directly with self-renewal, and it is instead the
non self-renewing lineages that generate tumours more rapidly and
with higher penetrance (Barrett et al., 2012). Such behaviour could
reveal a requirement for lineage-restricted pathways for initiating or
maintaining tumours.
Our ability to distinguish cell types in the brain allows us to
compare the tumourigenic potential of specific neural stem and
progenitor populations. For example, activation of oncogenes, such
as KRasG12D, or inactivation of tumour suppressors, such as p53,
Rb, PTEN, Arf or Nf1, has been used to directly address the
tumourigenic potential of different cells. These works reveal that
neural stem cells (NSCs) and progenitor cells are more readily
transformed than differentiated cell types, and embryonic radial glia
cells (RGCs) are more prone to transformation than postnatal stem
cells (Alcantara Llaguno et al., 2009; Jacques et al., 2010; Munoz
et al., 2013). Moreover, evidence points to astrocytes and
oligodendocyte progenitors as also having the potential to act as
the cells of origin in gliomas (Zong et al., 2015). As the majority of
astrocytomas are preferentially located in areas rich in neural
progenitor cells (Chow et al., 2011; Zong et al., 2015), the tumour-
initiating capacity of astrocytes has been difficult to assess, as they
co-express markers of neural precursor cells (e.g. GFAP). However,
with over 20% of astrocytomas formed in non-proliferative zones, it
follows that either GFAP-positive NSCs have migrated to distant
sites, or that tumours originate from mature astrocytes (Chow et al.,
2011). Multiple lines of evidence also support a role for NG2-
positive oligodendrocyte precursor cell transformation in glioma
(Liu et al., 2011; Persson et al., 2010), including histopathological
expression of oligodendrocyte precursor cell markers in human
samples, overlap between the molecular signature of proneural
subtype glioma and that of oligodendrocyte precursor cells, and the
great expansion of oligodendrocyte precursor cells in comparison
with NSCs, astrocytes or neurons upon tumour suppressor gene
inactivation and prior to malignant transformation.
The identification of the cell-of-origin in medulloblastoma has
been even more challenging because of the high degree of inter-
tumoural heterogeneity. Medulloblastomas can be classified into
discrete subgroups based on gene expression and tumour-driving
mutations (Gibson et al., 2010) (Fig. 1). Importantly, different
tumour subgroups arise from different cell types in distinct locations
and are hence likely to arise from different tumour-initiating
populations: group 1 medulloblstoma is SHH driven and originates
from granule neuron precursors in the cerebellar external granule
cell layer (Schüller et al., 2008; Yang et al., 2008); group 2
Table 1. Classification of brain tumours and their associated World
Health Organization (WHO) grade
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medulloblastoma is WNT driven and arises from progenitors in the
dorsal brain stem (Phoenix et al., 2016); group 3medulloblastoma is
associated with Myc overexpression in granule neuron precursors,
ventricular zone stem cells or in other classes of progenitors
(Kawauchi et al., 2012; Pei et al., 2012; Wang and Wechsler-Reya,
2014); and group 4 is thought to originate from deep nuclei
precursors located in the upper rhombic lip (Lin et al., 2016)
(Fig. 1B,C). Further refinement of these four groups into 12 distinct
subtypes through the combination of genome-wide DNA
methylation, gene expression and pathway analysis revealed that
the SHH group of tumours could be divided into four subtypes: α, β,
γ and δ (Cavalli et al., 2017). These subtypes correlatewith differing
prognoses, and SHH γ-subtype children who have excellent survival
rates could thus be included in the group of young patients treated
with reduced radiation in the future (Bavle and Parsons, 2017;
Cavalli et al., 2017). The classification of medulloblastoma based
on the tumour cell of origin, with an emphasis on understanding the
differences in the ensuing pathogenesis of disease, is probably the
best example of a tumour type where such an understanding could
inform therapeutic regimens for patient benefit.
Overall, it is clear that brain tumours arise from multiple cell
types that are distinguishable both by location and by degree of
differentiation, although the precise cell of origin is rarely clear.
Morphologically similar cancers may yet be shown to arise from
different cell populations. Moreover, mature brain cells are not
completely resistant to oncogene-mediated transformation, as
astrocytes and even mature neurons can dedifferentiate to form
gliomas in mice (Friedmann-Morvinski et al., 2012). However, the
general principle seems to hold that the more mature a cell is, the
more resistant it is to transformation.
Mechanisms by which stem cell-like phenotypes are acquired
While tumours can arise from progenitor populations, the extent
to which they must revert to a stem cell-like state to overcome
restrictions in progenitor cell proliferation as well as lineage
restriction is an area of debate. It is clear that progenitors can initiate
tumour growth in medulloblastoma and glioma [granule neuron
precursors in medulloblastoma and oligodendrocyte precursor cells
in gliomas (Liu et al., 2011; Persson et al., 2010; Schüller et al.,
2008; Yang et al., 2008)], while these cells give rise to progeny that
can differentiate into both to glia and neurons, a property of
multipotent stem cells. Oncogenic mutations could be present in
multipotent stem cells, but only result in tumourigenic potential
when cells adopt a more restricted progenitor cell identity,
suggesting an interaction between the particular mutation and the
developmental programme (Fig. 2). In addition, fate-restricted
progenitors could reacquire stem cell-like properties through a
process of dedifferentiation, providing them with the plasticity
necessary to differentiate into multiple lineages. The ability to revert
back to a tumourigenic glioma stem cell-like state can be achieved
by forced oncogene expression in differentiated glioblastoma cells
(Suvà et al., 2014) and even in mature post-mitotic neurons and
astrocytes (Friedmann-Morvinski and Verma, 2014) (Fig. 2). This
suggests a potential contribution of environmental factors and cell
cycle re-entry during the course of reversion. However, the interplay
between environmental factors and oncogenes, and the impact of
dedifferentiation and dysregulation of cell fate on cancer formation
have only recently been proposed for some epithelial tumours (Krah
and Murtaugh, 2016) and are not well defined for brain tumours.
In addition to dedifferentiation, an active impediment to
differentiation could also ‘trap’ cells in a proliferative pro-
tumourigenic state (Fig. 2). Mechanisms of differentiation failure
have been the subject of intensive studies as the unlocking of any
latent ability to differentiate could be exploited as a therapeutic
strategy to drive neural and glial tumour cells into a permanently
post-mitotic state (Fortier et al., 2010; Hu et al., 2013). Proof of
principle of this therapeutic approach is provided by acute
promyelocytic leukaemia in which differentiation therapy (all-
trans-retinoic acid/arsenic trioxide) negatively impacts proliferative
potential, extinguishes self-renewal and subsequently increases
survival from 10% to over 90% (de The and Chen, 2010). However,
attempts to drive glioblastoma cells into terminal differentiation
have, so far, been inconsistent (Carén et al., 2015; Park et al., 2017;
Piccirillo and Vescovi, 2006).
Althoughmuch evidence points to recapitulation of developmental
programmes in the behaviour of brain cancer cells, these could also be
undergoing an aberrant regenerative process that, in itself, could
exploit mechanisms originally active in adult or embryonic NSCs.
This is an exciting and yet poorly investigated topic and future
research should focus on understanding the similarities between
embryonic neural stem/progenitor cells, adult neural stem/progenitor
cells and injury-reactivated cells, and investigate the potential
contribution of regenerative responses to brain tumour formation
(Torper and Götz, 2017; Urbán and Guillemot, 2014).
Tracing the lineage progression of brain tumour cells
Although the highly proliferative capacity of fate-restricted
progenitors plays a significant role in tumour growth and
progression, therapies that target proliferation have drastically
failed, mainly because the resident slow-cycling stem-like cells can
become reactivated and cause tumour relapse (Hambardzumyan
et al., 2008; Vanner et al., 2014). To develop successful therapies, it
is thus essential that we understand not only the tumour cell of origin
GNP in EGL NPC in lRL and
dorsal brain stem 
NPC in VZ or EGL
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Fig. 1. Cell of origin in medulloblastoma subgroups. (A) Posterolateral view
of the mouse developing cerebellum. (B) Sagittal section of the developing
cerebellum showing the location of the precursors that give rise to the distinct
medulloblastoma subgroups shown in C. Sonic hedgehog-positive (SHH)
medulloblastomas derive from GNPs in the EGL (blue), WNT-positive
medulloblastomas derive from the lower RL and dorsal brain stem (yellow),
group 3 medulloblastomas are thought to originate from either VZ or EGL
progenitors overexpressing the oncogene Myc (grey) and group 4
medulloblastomas have been proposed to derive from cells with active LMX1A,
TBR2 and LHX2 super-enhancers in the NTZ that contains deep nuclei
originating from the upper RL (brown). Questionmarks under the cell of origin in
groups 3 and 4 highlight the difficulty in pinpointing a specific cell of origin for
these subgroups.Medulloblastomaclassification is also constantlyevolvingand
further subdivisions within these four subgroups have been recently reported
(see Cavalli et al., 2017). EGL, external granule cell layer; GNPs, granule
neuron precursors; lRL, lower rhombic lip; MB, medulloblastoma; NTZ, nuclear
transitory zone; RP, roof plate; uRL, upper rhombic lip; VZ, ventricular zone.
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and how it can acquire a stem cell signature, but also lineage
progression within the tumour. Efforts to study the fate of cells and
to establish whether aspects of a normal hierarchical lineage
progression are conserved during tumourigenesis have focused on
quantitative lineage-tracing assays. To this end, different studies
have used diverse and complementary approaches, such as analysis
of mutational landscape data, single-cell RNA sequencing, clonal
size distribution and quantitative statistical modelling to investigate
lineage progression and clonal evolution in medulloblastoma,
oligodendroglioma and glioblastoma.
Genomic analysis of individual human medulloblastomas
immediately post-diagnosis and after therapy showed that fewer
than 12% of diagnostic genetic events were present in the relapsed
tumour sample. Indeed, the genetic clone seen to dominate the
tumour was different before and after therapy; close analysis
revealed that the dominant clone in relapsed tumours arose from a
previous minor clone that was, nevertheless, present at initial
diagnosis (Morrissy et al., 2016). Similar results were obtained in
glioblastoma, in which recurrent tumours are thought to be seeded
by cells derived from the initial tumour at a very early stage of their
evolution (Johnson et al., 2014). This type of pattern would suggest
that genetic variations play a role in clonal evolution at recurrence or
after therapy. However more recent work has partially challenged
this view. Through single-cell RNA sequencing, Suvà and colleagues
have identified a hierarchical architecture in oligodendroglioma
reminiscent of a developmental programme, with evidence for an
undifferentiated compartment that shares a gene expression signature
with neural stem and progenitor cells, fuels tumour growth and
transitions into differentiation along the two glial lineages: astrocytes
and oliogodendrocytes (Tirosh et al., 2016; Venteicher et al., 2017).
Importantly, the authors suggest that this hierarchy is anchored in a
developmental programme and has not evolved through genetic
evolution, which could otherwisemodulate the patterns of tumour cell
self-renewal and differentiation. However, as the oligodendroglioma
could not be expanded through xenotransplantation, a complete
phylogenetic reconstruction was missing and genetic influences can
not be entirely ruled out.
In a similar vein, new findings have been reported on tumour
cell dynamics in glioblastoma using a novel clonal fate mapping
approach based on genetic barcoding previously applied to
mammary tumour models (Lan et al., 2017; Nguyen et al., 2015).
By combining DNA barcoding of primary human glioblastoma
cells with quantitative analysis of clone size following serial
xenotransplantation into mouse, Lan et al. have shown that the
observed heterogeneity in clonal expansion is not associated with
variability in the mutational landscape, but derives from stochastic
fate decisions of tumour cells obtained within a conserved
developmental-like hierarchy (Lan et al., 2017). In this model,
tumour expansion is driven by a subpopulation of slow-cycling
stem-like cells that renew while giving rise to a rapidly cycling
intermediate progenitor-like population, which self-renew and
generate short-lived non-dividing progeny. Interestingly, cells
isolated from primary glioblastoma have been shown to have a
transcriptional signature reminiscent of outer radial glia cells (Patel
et al., 2014; Pollen et al., 2015), a self-renewing developmental
precursor located in the basal regions of the human cerebral cortex
(Fietz et al., 2010; Hansen et al., 2010). This novel finding suggests
that similar mechanisms might regulate expansion and self-renewal
of tumour cells and of these normal developmental precursors. This
behaviour, which is highly reminiscent of lineage progression
during neural development, has also been proposed for SHH-driven
medulloblastoma. In the Ptch1 heterozygous mouse model of
medulloblastoma, studies of proliferation kinetics and genetic
lineage tracing have shown that slow-cycling Sox2-positive
stem-like cells at the apex of a hierarchy give rise to highly
proliferative intermediates (marked by Dcx and Ki67 expression)
that differentiate into NeuN-positive neurons, which then undergo
rapid apoptosis (Vanner et al., 2014). Whether the clonal dynamics
of tumour growth in medulloblastoma reflect that inferred from the
dynamics of tumour cells in glioblastoma remains unknown.
The studies discussed in this section not only support the
existence of seemingly conserved lineage hierarchies in brain
tumours that are reminiscent of a normal developmental
programme, but also shed light on the relative contribution of
genetic variation and developmental mechanisms to inter- and intra-
tumoural heterogeneity. This is an important area of study, as
resolution of the clonal dynamics and lineage progression of
neurological tumours could provide novel approaches to therapy. As
shown in the context of other epithelial tumours (Driessens et al.,
2012; Sánchez-Danés et al., 2016; Alcolea et al., 2014; Frede et al.,
2016), brain tumour growth could also rely on the preferential loss
of differentiating divisions, leading to a bias in cell fate decision
towards dividing daughter cells. Thus, manipulating this balance to
alter cell fate decisions, rather than inhibition of cell cycle, might
prove to be a more effective therapeutic approach. Another benefit


















Fig. 2. Mechanisms of ‘stemness’ acquisition in cancer. (A) Under physiological conditions, multipotent neural stem cells (NSCs) self-renew and differentiate
into fate-restricted progenitors, which are capable of lineage amplification and differentiation to the three main cell types in the brain: neurons (blue), astrocytes
(orange) and oligodendrocytes (yellow). (B) Cancer cells can arise from de-regulation of NSC self-renewal (curved bold arrow, I), from de-differentiation of cells that
revert back to a stemor progenitor-like state (dashed arrows, II) and/or from failed differentiation of stem (I) and progenitor (III) cells that are locked in a pro-proliferative
state and differentiate aberrantly (curved bold arrows, I and III). APC, astrocytic progenitor cells; NPC, neural progenitor cells; OPC, oligodendrocyte precursor cells.
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types of clonal behaviour characterized by differential sensitivity
to drugs. This has been shown, for example, in the mouse xenograft
study of human glioblastoma, which is seen to contain two types of
clones. A subpopulation of expanding clones, which depart from the
behaviour of the bulk population, become selected for during
temozolomide treatment, but are instead sensitive to the menin-
MLL inhibitor, an epigenetic drug previously shown to be effective
in H3.3 mutant paediatric glioblastoma (Lan et al., 2017). In
summary, dynamic analysis of lineage progression, in combination
with quantitative clonal analysis and genome-wide DNA and RNA
sequencing, can provide a useful framework for developing
effective combinatorial therapies.
Epigenetic regulation of tumourigenesis
Although some oncogenic events are shared across multiple tumour
types, distinct genetic lesions associated with specific types of
tumours point to intrinsic differences in the way cells of different
lineages respond to oncogenic assault. Moreover, lineage-specific
transcriptional regulators have also been identified as context-
dependent oncogenes and/or tumour suppressor genes, reinforcing
the idea that key genes that regulate normal developmental lineages
may become deregulated in cancer, subverting their normal function
and resulting in uncontrolled proliferation and suppression of
terminal differentiation (Garraway and Sellers, 2006; Vias et al.,
2008). Such lineage-specific oncogenic function is likely to rely on
the cell type-specific epigenetic environment in which oncogenic
activation occurs, and to intersect with tissue-specific self-renewal
and differentiation signalling pathways.
The contribution of chromatin dysregulation to neurological cancers
In eukaryotes, DNA is wound around a core of nucleosomal
histone proteins to form chromatin. Chromatin organization is of
fundamental importance in the establishment and maintenance of
cell-type specific transcriptional programmes during development
and differentiation, and imposes the environment in which tissue-
specific transcriptional regulators must act. Not surprisingly,
alterations to the chromatin landscape can profoundly impact cell
fate decisions in development and cancer. At its simplest level,
chromatin remodelling is achieved through the concerted activity of
proteins and enzymes that regulate histone methylation, histone
acetylation, DNA methylation, and nucleosome tri-dimensional
structure and repositioning (Jones et al., 2013). The importance of
chromatin regulators in various types of cancer is highlighted
by the recurrent copy number alterations or mutations at chromatin-
modifying genes. Importantly, certain types of chromatin-
modifying alterations are restricted to specific subgroups of
tumours, as has been shown in medulloblastoma (Northcott et al.,
2017; Robinson et al., 2012), and might thus impart lineage-specific
vulnerabilities to distinct types of tumour cells. Understanding these
vulnerabilities may provide insights into novel therapeutic
approaches, and indeed many novel agents targeting chromatin
modifiers are currently in development or in early clinical trials.
H3.3 variants in paediatric gliomas
Diffuse intrinsic pontine gliomas (DIPGs, now included in the
diffuse midline glioma classification – see Table 1) result in a
median survival of only 9 months. Studies of this devastating
malignancy have demonstrated that paediatric and adult gliomas
are biologically and molecularly distinct. The most prominent
difference lies in hotspot mutations in the gene encoding histone 3.3
variants, with only 0.2% of adult patients, yet 50% of paediatric
patients, carrying these mutations (Schwartzentruber et al., 2012;
Wu et al., 2012). The histone 3 variant 3 (H3.3) is cell-cycle
independent and is incorporated into genic euchromatin regions or
pericentromeric and telomeric regions by different associated
proteins: ATRX and DAXX. Interestingly, in addition to mutations
at key regulatory residues in histone H3.3, mutations have
been reported in ATRX and DAXX (Huether et al., 2014;
Schwartzentruber et al., 2012). The majority of DIPG patients
carry a H3.3 Lys27Met (K27M) missense mutation, whereas a
minority exhibit a H3.3 G34R/V mutation. Moreover, advances in
genomic and bioinformatic techniques have allowed the sub-
classification tumours based on common mutational patterns of
histones. An analysis of a large dataset of around 1000 samples of
paediatric and adult gliomas revealed that K27M and G34R/V H3.3
variants represent different biological subgroups (Mackay et al.,
2017); K27M H3.3 tumours are found in 70% of DIPG and non-
brainstem midline paediatric gliomas and exhibit selective
mutations in CCND2 and TOP3A, whereas H3.3G34R/V-mutant
tumours are restricted to the cerebral hemispheres and co-segregate
with mutations in the histone-associated proteins ATRX and TP53.
Methylation of H3.3 is reduced by the K27M mutation and this
results in disrupted transcription (predominantly de-repression) of
several cancer-associated genes (Bender et al., 2013; Chan et al.,
2013). Overexpression of H3.3K27M, alongside other co-operating
mutations, is required in the correct cell and, crucially, at the correct
developmental time (in this case pre-natally) to generate a mouse
model of paediatric high-grade glioma. This again demonstrates the
importance of the spatiotemporal context in moving from an
oncogenic assault to a full-blown tumour (Pathania et al., 2017).
Control of methylation by Polycomb and Trithorax-group proteins
Methylation of both DNA and histones plays an important role in
regulating gene expression levels. A recent genomic analysis across
the different medulloblastoma subgroups revealed that group 3
and 4, in particular, carry somatic copy number aberrations and have
transcriptional profiles that converge on deregulated methylation of
H3K4 and H3K27 (Huether et al., 2014). Polycomb (PcG) and
Trithorax (TrxG) protein complexes are responsible for epigenetic
histone modifications that either repress or promote gene
transcription, and several lines of evidence indicate that altered
activity of these epigenetic modifiers may contribute to the
neoplastic phenotype.
The methyltransferase EZH2, which is the enzymatic subunit of
the polycomb repressive complex 2 (Prc2), is responsible for
H3K27 trimethylation, a repressive mark that is tightly associated
with inactive gene promoters. EZH2 is upregulated in various
cancers, including medulloblastoma and glioblastoma, and it can act
as a critical regulator of neoplastic proliferation, maintenance of
stem cell-like features and inhibition of differentiation (Suvà et al.,
2009; Vo et al., 2017). For example, small-molecule inhibition of
EZH2 in glioblastoma and DIPG reduced tumourigenesis in vivo
(Lan et al., 2017; Mohammad et al., 2017; Wang et al., 2017),
whereas loss of EZH2 in medulloblastoma attenuated growth
and promoted differentiation in vitro (Alimova et al., 2012).
However, EZH2 inactivation in an in vivo mouse model of group 3
medulloblastoma resulted instead in accelerated tumour initiation
and progression, due to de-repression of the proto-oncogene Gfi1,
which cooperates with Myc (Vo et al., 2017). This reveals that
EZH2 can act as both an oncogene and a tumour suppressor gene,
depending on the context. Multiple other genes belonging to PRC1
and PRC2 complexes, including BMI1, EED and SUZ12 have been
found upregulated either in specific medulloblastoma subgroups or
across medulloblastoma generally.
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TrxG complexes sustain transcription via both their H3K4
methyltransferase activity and H3K27 demethylase activity that
opposes PcG mediated repression, and components of the TrxG
group of proteins have also been found to be mutated in high-grade
gliomas and medulloblastoma (Huether et al., 2014). Moreover,
the demethylase KDM6A (also called UTX) and the histone
methyltransferases mixed lineage leukaemia, MLL2 (KMT2D) and
MLL3 (KMT2C), display inactivating and truncating mutations,
suggesting tumour suppressive functions. Interestingly, KDM6A
and MLL2 mutations have been found to be mutually exclusive,
further reinforcing the likelihood that they regulate similar processes
(Dubuc et al., 2013).
Mutations in isocitrate dehydrogenase 1 (IDH1), and less
frequently in IDH2, occur in 80% of grade II and grade III
astrocytomas and oligodendrogliomas, and are also found in high-
grade glioblastomas that have arisen over time from these lower-
grade gliomas (Staedtke et al., 2016). IDHmutations disrupt cellular
metabolism. This ultimately leads to hypermethylation of histones
and CpG islands, a so-called methylator phenotype, that brings about
extensive dysregulation in gene expression (Turcan et al., 2012),
which works in conjunction with additional mutations to drive
tumourigenesis (Weller et al., 2015). Interestingly, progression to
higher grade disease is often accompanied by overall decrease in
methylation, but hypermethylation of a small subset of CpG islands
associated with developmental regulators, including FOX, SOX and
TBX family genes, which may ‘lock’ cells into a permanently self-
renewing state (Bai et al., 2016). IDH activity and the pathways it
regulates have therefore recently been proposed as a potentially
important therapeutic targets in gliomas (Malta et al., 2017).
Super-enhancer and bromodomain proteins
Recent excitement has accompanied the identification of enhancer
regionswheremultiple transcriptional regulators are bound, andwhich
direct a very high level of gene expression, so-called super-enhancers.
Super-enhancers are thought to be essential for maintenance of cell
identity (Hnisz et al., 2013), whereas aberrant super-enhancer
formation and/or maintenance may underlie both inappropriate
activation of oncogenic drivers and an alteration in cell fate and
differentiation (Chipumuro et al., 2014; Lovén et al., 2013). Super-
enhancers are characterised by very high levels of H3K27 acetylation.
This leads to the accumulation of bromodomains and extra-terminal
domain (BET) proteins, as well as more recruitment of the
transcriptional cyclin-dependent kinase CDK7, which directs high
levels of transcription (Larochelle et al., 2012; LeRoy et al., 2008;
Rahman et al., 2011). Inhibition of BET or CDK7 has been used to
target MYC-driven tumours in different contexts, as MYC expression
in tumours is frequently maintained at a high level by an associated
super-enhancer region (Sengupta and George, 2017). For example,
BET inhibition in multiple myeloma cells and CDK7 inhibition in
neuroblastoma cells led to preferential downregulation of super
enhancer-associated genes, including MYC and other genes
associated with the biology of the specific lineage of the tumour
(Chipumuro et al., 2014; Lovén et al., 2013). Strikingly, these drugs
show a remarkable selectivity for MYC-amplified cells. However,
super-enhancer activity is also important in nonMYC-driven tumours.
As described above, the majority of individuals with DIPG carry
H3.3 mutations that are often accompanied by a reduction in the
levels of PRC2-mediated H3K27 trimethylation. However, novel
epigenetic analyses demonstrate that several genes not only retain
H3K27 methylation but also showed increased H3K27 acetylation
(Piunti et al., 2017), an epigenetic mark that is typically indicative of
actively transcribed genes, and which correlates with BET protein
association. Inhibition of BET proteins and of CDK7 has been
used to successfully inhibit tumourigenesis in DIPG, preferentially
disrupting transcription at super enhancer-associated genes.Manyof
the dysregulated genes are specifically involved in neuronal-lineage
specification, including the bHLH factor ASCL1 (discussed below)
(Nagaraja et al., 2017). Thus, super-enhancers can mediate
transcriptional vulnerabilities that are specific to each tumour type
and can point to previously unknown mechanisms of tumour
pathobiology related to the lineage-specific transcriptional networks
of the tumour cell of origin, illustrated by DIPG and other types of
cancer (Chipumuro et al., 2014; Nagaraja et al., 2017).
The role of lineage-specific transcriptional regulators in
neurological cancers
Many transcription factors with well-characterised roles in
neurogenesis and development of the nervous system have
subsequently been identified as lineage-specific oncogenes and/or
tumour suppressor genes in cancers of the central nervous system
(CNS). This may illustrate the close relationship between normal
developmental processes and tumourigenesis, and may reflect the
influence of stem/progenitor cell positional identity on the response
to oncogenic pathways. Indeed, stem and progenitors cells located
in discrete brain regions and embedded in different supportive
niches possess unique transcription factor codes from patterning
processes (Azzarelli et al., 2015), as well as distinct growth
requirements that could impinge on their susceptibility to specific
oncogenic signals. Interrogating the expression and activity of
lineage-specific transcriptional regulators in different contexts may
shed light on the origin of nervous system cancers, as well as reveal
potential new therapeutic vulnerabilities.
Sox2
SOX2 is a prominent member of the sex-determining region (SRY)
box 2 family of proteins that have wide-ranging roles in the
developing embryo and in adult stem cells. Although eclipsed in
recent years by its identification as a key pluripotency factor, SOX2
has also been extensively studied in the context of its important roles
in nervous system development and adult NSC activity. Likely
reflecting these activities, SOX2 has emerged as a central player in
neurological cancers.
SOX2 is often highly expressed in glioblastoma and its knockdown
reduces proliferation and tumourigenicity in glioblastoma tumour-
initiating cells (de la Rocha et al., 2014; Gangemi et al., 2009; Garros-
Regulez et al., 2016). Mirroring its function in the maintenance
of normal NSCs, SOX2 appears to act within a transcriptional
network to propagate glioma-initiating properties and, therefore, acts
as a driver of cancer stem cell-like behaviour. A combination of the
transcriptional regulators Sox2, Olig2 and Zeb1 is robustly expressed
in genetically diverse glioblastomas and is sufficient to transform
astrocytes that have lost tumour suppressor gene pathways (Singh
et al., 2017). Moreover, the possible role of SOX2 in driving
gliomagenesis may also reflect its remarkable ability to facilitate
active dedifferentiation of more mature cell types, e.g. in
reprogramming of fibroblasts to induced pluripotent stem cells
(Takahashi et al., 2007) and to NSC-like cells (Lujan et al., 2012).
Forced expression of SOX2 in cooperation with FOXG1, another
component of the fibroblast-to-NSC reprogramming cocktail that has
also been implicated in glioblastoma, can impose a dedifferentiation
programme on astrocytes that results in reactivation of cell division
and acquisition of NSC-like characteristics (Bulstrode et al., 2017).
SOX2 expression also indicates a potential role in the aetiology of
paediatric tumours, including DIPG (Ballester et al., 2013) and SHH-
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type medulloblastoma (Vanner et al., 2014). Other SOX family
members have been shown to have various roles as oncogenes and
tumour suppressor genes in a variety of CNS tumours (de la Rocha
et al., 2014), and it seems reasonable to speculate that their roles
reflect a subversion of their normal developmental functions. Hence,
better characterisation of these normal functionsmay reveal additional
treatment vulnerabilities.
bHLH proneural transcriptional regulators
The main functions of proneural basic helix-loop-helix (bHLH)
transcription factors are to specify cell fate, to regulate NSC
proliferation, and to drive neuronal differentiation during embryonic
and postnatal development (Bertrand et al., 2002; Imayoshi and
Kageyama, 2014). Although mutations in proneural bHLHs have
not been consistently found in tumour samples, their expression is
altered in several neural and endocrine cancers, suggesting that
proneural proteins might play important roles in cancer initiation
and maintenance (Huang et al., 2014) (Table 2). In addition, non-
tissue-specific bHLH regulators, such as ID and HES proteins, have
also been implicated in regulating tumourigenesis (Lasorella et al.,
2014; Sang et al., 2010). The potential involvement of proneural
factors in tumourigenesis, and in particular lineage-specific factors,
such as ASCL1, OLIG2 and ATOH1, described below and in
Table 2, again points to retention and subversion of transcriptional
networks found in their normal counterpart cells.
ASCL1 in gliomagenesis
During embryonic and postnatal development, ASCL1 plays an
important role in the regulation of NSCs and oligodendrocyte
precursors (Parras et al., 2004; Raposo et al., 2015). ASCL1 is
frequently expressed in malignant brain tumours, including
oliogdendroglioma, diffuse astrocytoma and proneural type
glioblastoma, as well as in primary glioblastoma and lower grade
gliomas (Rheinbay et al., 2013; Rousseau et al., 2006;
Somasundaram et al., 2005). This expression may be a reflection
of ASCL1 expression in the tumour cell of origin, as well as its
functional role in neurogenesis.
ASCL1 expression is maintained in NSCs and glioma stem cells in
culture, where it is essential for their proliferation and self-renewal in
part through activation of Wnt signalling (Raposo et al., 2015;
Rheinbay et al., 2013). However, the specific level of ASCL1, i.e.
high versus low, does not strictly correlatewith proliferative properties
(Park et al., 2017). Instead, phenotypic differences that depend on the
expression level of ASCL1 are more likely to emerge when cells
undergo differentiation or in tumourigenic assays. Glioma stem cells
derived from individualswith highASCL1 expression remainedmore
competent to undergo terminal neuronal differentiation in response to
Notch inhibition compared with glioma stem cells expressing low
ASCL1 (Park et al., 2017). As high ASCL1 expression in these
patients apparently correlates with better clinical outcome, this has led
to the suggestion of using ASCL1-based patient stratification to
identify a subgroup of patients that can be effectively treated with
Notch inhibitors to bring aboutASCL1-mediated differentiation (Park
et al., 2017). Previous attempts to differentiate glioma stem cells as a
way to lock them permanently out of cell cycle have not been
successful, as cells rapidly re-enter a proliferative statewhen treatment
is removed and permanent epigenetic modifications indicative of
stable differentiation are not evident (Carén et al., 2015).
Table 2. Role and regulation of bHLH transcription factors in CNS tumours and neuroblastoma
Factor Tumour type Description Reference
ASCL1 Glioblastoma ASCL1HIGH cells retain neuronal differentiation competence and are sensitive to Notch
inhibitors
Park et al. (2017)
Astrocytoma, GBM ASCL1 is upregulated in grade II and II astrocytoma, and in secondary GBM Somasundaram et al. (2005)
Oligodendroglioma ASCL1 is a potential marker for oligodendroglial tumour Rousseau et al. (2006)
GBM ASCL1 regulates WNT signalling to promote GBM growth Rheinbay et al. (2013)
Astrocytoma Ascl1 is phosphorylated by ERK in development and in glioma Li et al. (2014)
Neuroblastoma ASCL1 is expressed in neuroblastoma cell lines. CDK-dependent ASCL1 phosphorylation
controls ASCL1 activity in neuroblastoma
Wylie et al. (2015)
Neuroblastoma ASCL1 expression correlates with poor prognosis. ASCL1 promotes proliferation in a
neuroblastoma cell line
Isogai et al. (2011)
Neuroblastoma High ASCL1 expression negatively correlates with differentiation of neuroblastoma cells Kasim et al. (2016)
OLIG2 Glioma Olig2 and its phosphorylation regulates NPC proliferation in development and gliomagenesis (Ligon et al., 2007; Sun et al.,
2011; Zhou et al., 2017)
Glioma In combination with other transcription factors, Olig2 can reprogram cells into tumour-initiating
cells.
Suva et al. (2014)
Glioma Oncogene-mediated reprograming reactivates a transcriptional regulatory network that
includes Olig2
Singh et al. (2017)
Glioma Olig2 forms a positive regulatory loop with EGFR, which is important for GSC stem cell
maintenance




OLIG2 is expressed in all tumours, in particular in oligodendrogliomas (Marie et al., 2001; Ligon
et al., 2004; Rousseau
et al., 2006)
Glioma Olig2 antagonizes p53 activity and response to genotoxic damage Mehta et al. (2011)
ATOH1 Medulloblastoma Atoh1-knockout animals do not develop tumours Flora et al. (2009)
Medulloblastoma Positive-feedback loop between Atoh1 and Shh sustains GNP proliferation in
medulloblastoma. Shh protects Atoh1 from phosphorylation-dependent Atoh1 degradation
(Ayrault et al., 2010; Forget
et al., 2014)
Medulloblastoma ATOH1 contributes to medulloblastoma dissemination Grausam et al. (2017)
Medulloblastoma BMP2 and BMP4 promote ATOH1 degradation and thus prevent medulloblastoma formation Zhao et al. (2008)
Medulloblastoma Granule neuron precursor commitment necessary for medulloblastoma formation (lineage
tracing)
(Schüller et al., 2008; Yang
et al., 2008)
Medulloblastoma ATOH1 expression in a subset of patients Salsano et al. (2004)
ASCL1, achaete-scute homolog 1; ATOH1, atonal homolog 1; CDK, cyclin-dependent kinase; EGFR, epidermal growth factor receptor; GBM, glioblastoma;
OLIG2, oligodendrocyte transcription factor 2.
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Treatment of glioma cells with bone morphogenetic protein
(BMP) causes cells to enter a state of reversible quiescence
characterised by astrocytic marker expression (Carén et al., 2015;
Martynoga et al., 2013; Park et al., 2017). In contrast, ASCL1-
driven neuronal differentiation may lock cells in a post-mitotic state,
re-imposing a normal developmental trajectory. Ascl1 has been
shown to have roles in stem cell quiescence, as well as in stem/
progenitor cell proliferation and differentiation during development
and in adulthood, and it would be interesting to understand more
about how these potentially opposing activities are controlled in
normal development and subverted in cancer (Carén et al., 2015;
Martynoga et al., 2013; Urbán et al., 2016).
The many roles of ASCL1 in stem/progenitor regulation indicate
that its activity must be tightly controlled and, indeed, post-
translational regulation by phosphorylation has been described. For
example, multi-site phosphorylation by extracellular signal-
regulated kinase ERK biases Ascl1-positive progenitors towards a
proliferative glial program responsible for astrocytoma initiation (Li
et al., 2014). Moreover, ASCL1 is highly phosphorylated by cyclin-
dependent kinase (CDK) during embryonic development and
neuronal reprogramming. In these contexts, phosphorylation of
ASCL1 restrains its ability to promote differentiation, an effect
analogous to that described for other proneural bHLHs in
development and cancer (Ali et al., 2014; Azzarelli et al., 2017).
In the future, it will be important to explore the integration of ERK
and CDK-mediated ASCL1 phosphoregulation in glioma initiation
and maintenance, and to explore whether inhibition of ASCL1
phosphorylation is a rational strategy with which to decrease
tumourigenicity by potentiating glioma stem cell differentiation. In
addition to a role in brain cancer biology, ASCL1 is expressed in
various neuroendocrine tumours of the lung (Borromeo et al., 2016;
Jiang et al., 2009), prostate and intestine, and in neuroblastoma
(Isogai et al., 2011; Kasim et al., 2016; Wylie et al., 2015),
indicating a potentially morewidespread role in tumourigenesis (see
Table 2).
OLIG2 in gliomagenesis
The transcriptional regulator OLIG2 cannot strictly be considered a
‘proneural’ transcription factor, since its main function is to induce
gliogenesis and inhibit neurogenesis in oligodendrocyte precursor
cells, although it also plays a role in motor neuron specification in
the spinal cord (Lu et al., 2002; Novitch et al., 2001; Takebayashi
et al., 2002). Potentially acting as a lineage-specific oncogene,
OLIG2 is expressed in all cases of diffuse paediatric and adult
human gliomas regardless of grade (Ligon et al., 2004; Marie et al.,
2001). OLIG2 is required for proliferation of multipotent neural
progenitors and for glioma formation in a mouse model of
gliomagenesis and it is also expressed in replicating
oligodendrocyte precursor cells where it cooperates with ASCL1
to specify oligodendrocytes (Ligon et al., 2007; Parras et al., 2004).
In these contexts, its activity is controlled by phosphorylation of
three specific serines, which results in sustained progenitor
proliferation and glioma stem cell propagation, in part through
repression of the CDK inhibitor CDKN1A (Mehta et al., 2011; Sun
et al., 2011). More recently, the kinases responsible for OLIG2
phosphorylation have been identified and targeted by small
molecule inhibitors that reduce gliomagenesis and increase
survival in a BRAFV600E mouse model of paediatric glioma
(Zhou et al., 2017). Importantly, OLIG2 phosphorylation is
involved in a positive regulatory loop with receptor tyrosine
kinases such as EGFR, which is essential for glioma stem cell
maintenance in vitro (Kupp et al., 2016).
In addition to the roles of OLIG2 in glioma stem cell growth,
tumour progression and differentiation, a role in tumour initiation,
e.g. by promoting cell fate reprogramming of more differentiated
cell types into stem-like cancer cells, is possible. Combined
induction of three transcription factors (POU3F2, SOX2, SALL2)
with OLIG2 (but not with ASCL1) in differentiated glioblastoma
generates cells capable of initiating tumours with high efficiency
(Suvà et al., 2014). Moreover, Olig2 has been recently identified as
a key component of the transcriptional regulatory network activated
upon combination of tumour suppressor and oncogene mutations in
astrocytes (Singh et al., 2017). This demonstrates that oncogene-
mediated dedifferentiation/reprogramming could directly reactivate
these lineage-specific stem/progenitor genes.
ATOH1 in medulloblastoma
ATOH1 is expressed in granule neuron precursors of the postnatal
cerebellum and is highly expressed in SHH-type medulloblastomas
(Table 2) (Salsano et al., 2004). Although Atoh1 overexpression is
not sufficient to drive full tumourigenesis, commitment to the
Atoh1-positive granule neuron precursor lineage is an essential
requirement for medulloblastoma formation (Schüller et al., 2008),
indicating essential crosstalk between developmental and
tumourigenic programmes. Atoh1 activity works to drive
medulloblastoma only in the context of underlying Shh mutations,
whereas Atoh1 loss of function prevents medulloblastoma
formation due to decreased granule neuron precursor proliferation
and impaired Shh signalling (Flora et al., 2009; Grausam et al.,
2017). Moreover, positive feedback exists between Atoh1 and Shh,
whereby Atoh1 maintains granule neuron precursors in a Shh-
responsive state, in part through the activation of the Shh target Gli2;
in turn Shh sustains Atoh1 expression and granule neuron precursor
proliferation (Ayrault et al., 2010; Flora et al., 2009). Thus, Atoh1
function in granule neuron precursors and its interaction with Shh
signalling represents the best example of how lineage-specific
regulatory pathways result in selective vulnerabilities to specific
oncogenic mutations.
Regulation of Atoh1 protein expression and stability is crucial for
lineage progression and granule neuron precursor differentiation;
Atoh1 destabilization and degradation, which coincides with
NeuroD1 upregulation, is a key requirement for progression down
the granule neuron lineage (Butts et al., 2014). Thus, proliferating
Atoh1-positive granule neuron precursors in medulloblastoma may
be locked in a pro-tumourigenic state resulting from a failure to
properly differentiate due to sustained levels of Atoh1. The
mechanisms that control Atoh1 stability are beginning to be
uncovered, revealing a crucial role for phosphorylation-mediated
degradation and for components of the BMP signalling pathway
(Forget et al., 2014; Zhao et al., 2008). In common with the
regulation of other bHLH proneural genes (Ali et al., 2011, 2014;
Azzarelli et al., 2017; Hardwick and Philpott, 2015; Hindley et al.,
2012), additional phosphorylation events potentially mediated by
CDKs may play a more widespread role in controlling Atoh1
activity in both normal granule neuron precursors and in
medulloblastoma.
Conclusions
Much attention has been paid to the unpredictable heterogeneity of
brain tumours and their aggressive growth characteristics, which
have been used to explain their general resistance to treatment (Ellis
et al., 2015; Gajjar et al., 2014). However, what is now emerging is a
picture of cell behaviour that is far from chaotic. Instead, recent
work suggests that, even though tumour cells have widespread
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genetic alterations, they may retain predictable behaviours that echo
the proliferation and differentiation programmes from earlier times
in development, and/or those seen in the context of adult stem/
progenitor-based homeostasis or injury response that recapitulate
these developmental programmes (Lan et al., 2017; Tirosh et al.,
2016). Recapitulation of developmental phenotypes is even stronger
in many paediatric tumours, where heterogeneity often arises from
different behaviours of distinct developmental precursors.
Indicative of an underlying hijacking of neurodevelopment
programmes, a number of transcriptional regulators of developmental
neurogenesis act as lineage-specific oncogenes in CNS cancers.
Genes such as ASCL1 and ATOH1 are predominantly expressed in
embryonic and postnatal neurological development, and make
appealing targets for therapy, although attention should be paid to
the residual function of these genes in the small population of adult
NSCs (Urbán et al., 2016) and to potential roles in regeneration after
injury. Although transcription factors generally make poor drug
targets, the manipulation of post-translational modifications of
proneural proteins is emerging as a potential way to control the
transcriptional activity of these genes (Ali et al., 2014; Wylie et al.,
2015), and points to the existence of vulnerabilities that are specific
to aberrant progenitor cells.
Although killing cancer cells is almost always the goal of current
therapies, if CNS cancers arise from a dysregulation or stalling of
developmental processes, an exciting possibility emerges that
reactivation of a programme of differentiation will ultimately
generate post-mitotic cells, and thus halt tumour growth (Wang and
Chen, 2008). This idea, referred to as differentiation therapy, has
been long discussed, and may become a reality as we begin to better
understand what controls both lineage progression and the balance
between proliferation and differentiation in normal and malignant
tissues. In particular, targeting multi-site phosphorylation of the
proneural proteins that act as master regulators of proliferation and
differentiation throughout the CNS should be further explored as a
potential new way to tip the balance of stem and progenitor cells in
favour of the post-mitotic differentiated state.
Beyond the promise and obvious challenges of targeting
individual transcriptional networks, our understanding of how the
wider epigenetic landscape influences fate choice, proliferation and
differentiation is constantly improving. A clear goal is to use drugs
that can influence the epigenome to change the fate and behaviour of
cells in response to the endogenous transcriptional programmes,
although the specificity of this approach in vivo remains to be tested
fully. Another area in its infancy and yet to be explored fully in the
CNS is the concept that changing the tumour microenvironment
may lead to changes in behaviour of the tumour cells themselves; by
manipulating the niche, we may shut down the tumour stem cell-like
programme. Such a possibility has been suggested by work in other
tissues but remains open for investigation in the nervous system
(Burger and Peled, 2009; Calabrese et al., 2007; Tauriello et al.,
2018).
Overall, it is clear that our understanding of the behaviour of brain
tumour cells is growing rapidly and will be further enhanced by
understanding how aberrant tumour cell behaviour often represents
a reversion to a dysregulated developmental phenotype. If we are to
further understand this phenomenon and to exploit emerging
vulnerabilities that result in either the death or differentiation of
tumour cells, we need to have more engagement between
developmental biologists and cancer biologists. After all, in many
ways cancer is ‘development gone wrong’, so developmental
biologists are as well placed as any scientists to help understand and
treat these devastating diseases.
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